Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Kainos Medicine Inc.

Dooseop Kim

Sander G Mills

Malcolm MacCoss

Nathan B Mantlo

William J Greenlee

Paul E Finke

Kevin Tyler Chapman

Arthur A Patchett

Prasun K Chakravarty

Ann E Weber

Emma R Parmee

Charles G Caldwell

Malcolm Maccoss

Shawn P Walsh

Alexander Pasternak

Barbara A Pio

Dong-Ming Shen

Scott D Edmondson

Jeffrey John Hale

Christopher L Lynch

Jinyou Xu

Bryan Oates

Shrenik K Shah

Haifeng Tang

Christopher Alan Willoughby

Jennifer L Loebach

Lihu Yang

Michael H Fisher

Peter J Sinclair

Jinlong Jiang

Fa-Xiang Ding

Zhi-Cai Shi

Harry R Chobanian

Linda L Chang

Shuzhi Dong

Ralph A Rivero

Ramzi Farah Sweis

Liping Wang

Jessica Frie

Aurash Shahripour

Stephen E De Laszlo

Julianne A Hunt

Liya Chen

Scott C Berk

Shankaran Kothandaraman

Brian Cato

Florida Kallashi

Kerry A Hilfiker

Ravi N Guthikonda

Jennifer Kowalchick

Amjad Ali

Wallace T Ashton

Songnian Lin

Ronald M Kim

Ravindra N Guthikonda

Christopher Francis Thompson

Yan Guo

Cameron James Smith

Linda Brockunier

Xibin Liao

Weiguo Liu

Joseph Leslie Duffy

Kevin Michael Belyk

Yuping Zhu

Timothy Allen Blizzard

Gui-Bai Liang

Qinghong Fu

Gayle E Taylor

Nazia Quraishi

Kothandaraman Shankaran

Reynalda Keh Dejesus

Tomasz W Glinka

Candido Gude

Reynalda De Jesus

Sunmi Shin

Keith Rosauer

Amy Gentry

Juhan Bok

Arthur A Pastchett

Michael Fisher

Yuan Cheng, Legal Representative

Jennifer E Kowalchick

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassim channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

The invention provides a novel compound having activity against diacylglycerol O-acyltransferase type 1 (DGAT1); a pharmaceutical composition for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 comprising said compound; a method for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 in an individual comprising administering said compound to the individual in need thereof; and a use of said compound for the manufacture of a medicament for preventing or treating a disease, disorder or condition modulated by DGAT1 inhibition.

Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. 

This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. 

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.

CETP inhibitors derived from benzoxazole arylamides

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes

Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic tricyclic compounds

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

CETP inhibitors

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes

The present invention is directed to compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved 

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes

&#x3b2;-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Pyrrolidine compounds of Formula (I), (wherein R, R, R, R, R, R, R, Rand Rare defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described 

Pyrrolidine modulators of CCR5 chemokine receptor activity

Growing community of inventors

Westfield, NJ, United States of America

Dooseop Kim